We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Saliva Culture Superior to Neonate Molecular Screening for CMV

By LabMedica International staff writers
Posted on 17 May 2010
A molecular screening test, using heel-prick blood, was not consistently sensitive enough to detect a congenitally transmitted viral infection in neonate blood samples. More...
The samples collected on filter paper are routinely used to test for metabolic and genetic diseases.

The test using real-time polymerase chain reactions (RT-PCR) on dried blood samples (DBS) were compared with saliva culture methods to detect Cytomegalovirus (CMV). The key feature of the RT-PCR procedure is that the amplified DNA is detected as the reaction progresses in real time rather than at the end of the process. The common methods for detection of products in real-time PCR use either nonspecific fluorescent dyes that intercalate with any double-stranded DNA, or sequence-specific DNA probes consisting of oligonucleotides that are labeled with a fluorescent reporter. Single-primer and two-primer RT-PCR systems were used to detect the fluorescent copies of the CMV DNA. The results were published online on April 2010 in the Journal of the American Medical Association (JAMA).


The samples were collected from infants born at seven United States medical centers as part of the National Institute on Deafness and Other Communication Disorders' CMV and Hearing Multicenter Screening (CHIMES) Study (NIDCD; Bethesda, MD, USA). Blood samples taken by heel pricks from neonates are routinely tested for such diseases as hyperthyroidism and sickle cell anemia and could therefore also be used in this study. As CMV infection is a leading cause of sensorineural hearing loss, both of which may be unapparent in the newborn, and at present, the only way to detect the virus is the labor-intensive tissue culture method.

The lead team at the University of Alabama at Birmingham Hospital (Birmingham, AL, USA), tested the diagnostic accuracy of the RT-PCR system for CMV in 20,448 babies. The saliva culture method detected 91/92 that were confirmed to have congenital CMV infection. The single primer RT-PCR was used on 11,422 samples could only detect 17/60 confirmed cases, while the 2-primer set found only 11 positives from the 32 proven cases of the 9,026 samples screened.

In the United States there are an estimated 20,000 to 40,000 babies born each year with congenital CMV. Hearing loss may occur in 10% to 15% due to the inapparent infections, which may have a late or progressive onset. Suresh Boppana, M.D, coprincipal investigator of the study, said "that a screening test needs to have a sensitivity of at least 95%" and therefore the 30-40 percent achieved on the dried blood meant more than half the infection would have been overlooked. A new study is in progress to test RT-PCR screening of saliva, which is known to be full of viruses in babies with congenital CMV. The saliva examination is noninvasive and needs minimal processing.

Related Links:

National Institute on Deafness and Other Communication Disorders
University of Alabama at Birmingham Hospital




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Thyroid Test
Anti-Thyroid EIA Test
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.